How to Develop CK1α Degraders: Degrader Types and Structural Design

* Please be kindly noted that our services and products are intended for research use by organizations or companies and are not intended for individual use.

Consult with Our Experts

What Is CK1α (CSNK1A1), and Which Forms of the Target Are Amenable to Degrader Development?

Casein kinase 1 alpha (CK1α), encoded by the CSNK1A1 gene, is a serine/threonine protein kinase involved in several fundamental cellular processes, including Wnt/β-catenin signaling, p53 regulation, cell-cycle progression, apoptosis, and intracellular protein trafficking. CK1α phosphorylates a wide range of protein substrates, often recognizing phosphorylation-dependent motifs and acidic amino acid environments surrounding the target serine or threonine residues. Its biological activity therefore depends not only on its catalytic function but also on its subcellular localization, protein-interaction partners, and access to specific substrate populations.

Human CK1α contains 337 amino acids in its predominant isoform, with a molecular mass of approximately 38.9 kDa. Its structure consists of an N-terminal kinase domain and a C-terminal regulatory region. The kinase domain adopts the conventional bilobal protein kinase fold, with an N-terminal lobe dominated by β-strands and a C-terminal lobe containing predominantly α-helical elements. The ATP-binding pocket and substrate-recognition region are located within the cleft between these two lobes. The C-terminal region contains regulatory sequences that influence kinase activity, autophosphorylation, and interactions with cellular partners.

An important structural feature for degrader development is the CK1α N-terminal region. The first approximately 90 amino acids contain a β-hairpin-containing segment, with residues I35-G40 forming a particularly important part of the degron recognized by CRBN-based molecular glue degraders. This region provides a natural protein-recognition surface that can be exploited without requiring a conventional small-molecule inhibitor to occupy the ATP pocket. The structural accessibility of this N-terminal degron explains why CK1α is a particularly interesting molecular glue target despite the challenges associated with developing highly selective kinase-binding ligands.

CSNK1A1 also undergoes alternative splicing, producing four commonly described CK1α forms: CK1αNI, CK1αS, CK1αL, and CK1αLS. These variants differ through the presence or absence of two inserts. The L insert contains 28 amino acids within the kinase domain, whereas the S insert contains 12 amino acids near the C-terminus. The L insert includes a nuclear localization signal and can influence the intracellular distribution of CK1α. CK1αSN is another described form with an N-terminal truncation. Because the N-terminal region contains the molecular glue-responsive degron, N-terminal truncation deserves particular attention when evaluating whether different CK1α forms retain susceptibility to CRBN-mediated degradation.

CK1α should also be distinguished from other members of the CK1 kinase family, including CK1β, CK1γ1-3, CK1δ, and CK1ε. Although these proteins share conserved kinase-domain architecture, their regulatory regions, substrate preferences, and cellular distribution differ. CK1α-like, encoded by the separate gene CSNK1A1L, is another relevant comparison because of its high sequence similarity to CK1α. These related proteins should be included in selectivity studies rather than assuming that a degrader developed against CK1α will automatically distinguish all closely related kinases.

Several CK1α structural and functional characteristics are particularly relevant to degrader development:

• N-terminal β-hairpin degron: The I35-G40 region provides the established recognition surface for CRBN-dependent molecular glue degradation. G40 is particularly important for productive ternary-complex formation.
• ATP-binding cleft: The kinase-domain pocket offers a potential recognition site for inhibitor-derived PROTAC warheads, although direct CK1α ATP-site PROTAC examples remain limited.
• Substrate-binding surface: The cleft between the kinase-domain lobes participates in substrate recognition and includes regions associated with MDMX interaction and recurrent CK1α mutations.
• Regulatory C-terminal region: Alternative splicing, phosphorylation, and protein interactions can influence CK1α activity and localization, potentially affecting degrader accessibility and cellular responses.
• Protein-interaction partners: MDMX and SACK1-family scaffold proteins provide additional opportunities for investigating CK1α-associated protein complexes and context-dependent degradation.

Table 1. CK1α Structural Features and Their Implications for Degrader Development.

What Have CK1α Degrader Studies Revealed About Molecular Glue Design and Development?

CK1α degrader research has primarily advanced through the development of cereblon (CRBN)-recruiting molecular glue degraders rather than conventional bifunctional PROTACs. Lenalidomide provided the foundational evidence that CK1α can be recruited to the CRL4^CRBN ubiquitin ligase complex and subsequently degraded through the ubiquitin-proteasome pathway. However, its CK1α degradation activity is relatively weak and incomplete, creating a need for more potent and selective molecular glue structures.

Early scaffold diversification demonstrated that modifying the solvent-exposed region of a CRBN-binding molecule can substantially change its neosubstrate profile. FPFT-2216 provided an early molecular glue scaffold capable of degrading CK1α together with PDE6D, IKZF1, and IKZF3. Subsequent chemical derivatization produced TMX-4116, which showed improved selectivity toward CK1α degradation. These studies established that the substrate specificity of CRBN-recruiting molecules can be modified through relatively focused structural changes rather than requiring a completely new E3 ligase system.

A second important development came from the structure-guided optimization of lenalidomide-derived compounds. SJ7095 showed potent CK1α degradation but also recruited IKZF1 and IKZF3. Further optimization of its solvent-exposed aromatic substituent produced SJ0040 and SJ3149. The introduction of a 3-methyl-benzamide group in SJ0040 improved CK1α degradation, while replacing this substituent with a 3-amino-benzisoxazole group in SJ3149 further enhanced potency and selectivity. The crystal structure of the CK1α-CRBN-DDB1-SJ3149 complex provided direct structural evidence explaining how the optimized substituent stabilizes the target-ligase interface.

Parallel research has expanded CK1α degradation toward dual-target molecular glue designs. DEG-35 emerged from the screening and optimization of CRBN ligands containing a naphthamide scaffold and demonstrated degradation of both CK1α and IKZF2. Subsequent scaffold replacement produced DEG-77, which retained dual-target activity while improving solubility, metabolic stability, and selectivity. These findings demonstrate that molecular glue development can be directed toward a defined multi-target degradation profile rather than simply maximizing the degradation of one neosubstrate.

Additional chemical diversification strategies have produced dCK1α-1 and dCK1α-2, as well as the QXG series. The dCK1α compounds demonstrate how modifying the target-facing heterocyclic scaffold and solvent-exposed substituents can improve degradation potency and molecular properties. The QXG series provides another example of systematic scaffold optimization: QXG-0629 was an initial hit with activity against several CRBN neosubstrates, whereas QXG-0632 and QXG-6442 showed improved CK1α selectivity. In particular, QXG-6442 demonstrated the importance of the heterocycle attachment position and the distance between the CRBN-binding core and the target-recognition element.

Collectively, these studies reveal four important principles for CK1α molecular glue development:

• CRBN-binding core preservation: The glutarimide-containing region must maintain its essential interactions with CRBN. Modifications should focus on solvent-exposed regions unless structural evidence supports changes to the anchoring pharmacophore.
• Target-facing substituent optimization: Aromatic and heteroaromatic substituents can establish additional contacts with CK1α and improve ternary-complex formation, as demonstrated by SJ3149 and QXG-6442.
• Scaffold geometry matters: Attachment position, bond type, interfragment distance, and conformational flexibility can determine whether a molecule retains degradation activity.
• Potency and selectivity require separate optimization: A potent CK1α degrader may also recruit other CRBN neosubstrates. Proteome-wide profiling is therefore important when selecting lead structures.

Table 2. Representative CK1α Molecular Glue Degraders and Their Structural Design Features.

CRBN-Directed Molecular Glue Degraders Engaging the CK1α N-Lobe β-Hairpin Degron

Target Site: The CK1α β-Hairpin Degron and Its CRBN Contact Surface

The most established molecular glue strategy for CK1α targets its N-terminal domain rather than the ATP-binding pocket. Structural studies of the CK1α-CRBN-lenalidomide complex identified an N-terminal region comprising approximately the first 93 amino acids as an important recognition element. Within this region, the β-hairpin degron containing residues I35-G40 plays a central role in CRBN recruitment. Unlike a conventional kinase inhibitor that occupies a defined catalytic pocket, a molecular glue stabilizes a protein-protein interaction between the exposed CK1α degron and the CRBN surface.

Gly40 is particularly important for this recognition mechanism. Its small side chain supports close molecular packing at the CK1α-CRBN interface. Replacing Gly40 with asparagine (G40N) disrupts productive molecular recognition and makes CK1α resistant to degradation by representative CRBN-directed molecular glues. This mutation provides an important experimental control for confirming whether a candidate compound depends on the established N-terminal degron.

Other residues around the degron contribute additional binding interactions. SJ3149 forms a hydrogen bond with CK1α Lys18 and hydrophobic contacts involving Val20 and the I35-G40 β-hairpin loop. These interactions help stabilize the CK1α-CRBN interface and explain why SJ3149 produces stronger degradation than the original lenalidomide scaffold. The structural evidence also shows that the target-recognition surface extends beyond the Gly40 residue itself, providing opportunities to optimize adjacent molecular contacts.

The CRBN side of the interface is equally important. Structural analysis of the CK1α-CRBN-DDB1-SJ3149 complex revealed interactions involving CRBN His353 and Glu377. The benzisoxazole substituent of SJ3149 extends toward the solvent-exposed region of CRBN, where it establishes additional hydrogen-bonding interactions. This arrangement illustrates how a target-facing substituent can contribute to both CK1α recognition and stabilization of the recruited E3 ligase complex.

For structure-guided design, the CK1α N-terminal domain should therefore be analyzed as a complete recognition surface rather than as an isolated short peptide sequence. Structural modeling should consider Lys18, Val20, the I35-G40 degron loop, and the surrounding solvent-accessible surface. The conformation of this region should also be evaluated in the context of the CRBN-DDB1 complex to identify substituent positions that can improve ternary-complex formation without disrupting the essential degron contacts.

Glue Scaffold Selection: IMiD-Derived Cores and Neosubstrate Selectivity Tuning

Lenalidomide provides the most established starting scaffold for CRBN-directed CK1α molecular glue development. Its glutarimide ring anchors the molecule within the tri-tryptophan binding pocket of CRBN, while the isoindolinone portion contributes to the surrounding molecular recognition environment. Importantly, thalidomide, lenalidomide, and pomalidomide do not produce identical neosubstrate profiles. Among these closely related structures, lenalidomide provides the established reference for CK1α recruitment, demonstrating that relatively small structural differences can strongly influence substrate recognition.

The SJ7095-to-SJ3149 optimization series demonstrates how modifying the solvent-exposed region of the CRBN-binding scaffold can improve CK1α selectivity. SJ7095 contains an extended aromatic substituent that was proposed to interact with the CRBN surface around Phe150, contributing to ternary-complex stabilization. However, its degradation profile included IKZF1 and IKZF3 in addition to CK1α. Subsequent optimization focused on changing the substitution vector and introducing additional interactions with the CK1α degron.

SJ0040 introduced a 3-methyl-benzamide substituent, producing improved CK1α degradation with reduced IKZF1 recruitment. Further replacement of this group with a 3-amino-benzisoxazole substituent produced SJ3149. The latter structure establishes additional interactions with CK1α Lys18 and the CRBN surface, resulting in a more favorable degradation profile. This progression demonstrates that the substituent attached to the CRBN-binding core should be designed according to the geometry of the complete target-ligase interface rather than optimized solely for CRBN affinity.

The QXG-6442 series provides another useful structure-activity relationship example. QXG-0629 initially contained an isoquinoline substituent attached to the lenalidomide-derived isoindolinone framework. Replacing isoquinoline with quinoline produced QXG-0632, while further chemical optimization identified QXG-6442, which contains a 2-imidazo[1,2-a]pyridine-carboxamide recognition element. Modeling suggests that the heterocyclic nitrogen can form a hydrogen bond with CK1α Lys18, while the carbonyl group contributes an additional interaction with CRBN His353.

The QXG series also illustrates the importance of the isoindolinone framework and the relative position of the target-facing substituent. Replacing the isoindolinone core with a phthalimide structure substantially reduced CK1α degradation. Adding an additional methylene group between the molecular fragments also eliminated degradation in selected analogs. These findings show that maintaining the correct spatial arrangement is essential even when the CRBN-binding pharmacophore remains present.

• Core selection: Start with a lenalidomide-derived glutarimide-isoindolinone scaffold when reproducing the established CK1α recognition mechanism. Preserve the glutarimide interactions required for CRBN binding.
• C5 substituent optimization: Explore aromatic and heteroaromatic substituents that extend toward the CK1α degron, using the 3-methyl-benzamide and 3-amino-benzisoxazole structures as representative design precedents.
• Hydrogen-bond acceptor placement: Consider nitrogen-containing heterocycles capable of interacting with CK1α Lys18. The imidazo[1,2-a]pyridine motif in QXG-6442 provides a useful example.
• Neosubstrate selectivity: Compare CK1α degradation with IKZF1, IKZF2, IKZF3, GSPT1, WEE1, and other relevant CRBN-recruited proteins when modifying the target-facing scaffold.
• Scaffold diversification: Explore alternative bicyclic and heteroaromatic structures when solubility, metabolic stability, or selectivity is insufficient, while retaining the essential CRBN-binding pharmacophore.

Linker Design: Why Linker-Free Glues Work Here and When Tethering Becomes Necessary

Unlike conventional PROTACs, established CK1α molecular glues do not require a separate target-binding ligand connected to an E3 ligase ligand through a long bifunctional linker. Instead, the CRBN-binding molecule itself stabilizes the interaction between CRBN and the CK1α N-terminal degron. The glutarimide-containing core anchors the compound to CRBN, while a directly attached aromatic or heteroaromatic substituent helps establish the target-facing recognition surface. This compact architecture is one of the main reasons why CK1α can be degraded without a conventional ATP-pocket warhead.

Although a traditional PROTAC linker is absent, the chemical connection between the CRBN-binding core and the target-facing substituent remains a critical structural variable. The SJ3149 series demonstrates that changing the substitution vector can determine whether an additional substituent reaches the CK1α degron while preserving the essential CRBN interactions. The C5 attachment strategy provides a useful precedent for positioning a target-facing group toward the β-hairpin recognition surface.

The QXG-6442 optimization series provides more direct evidence of the importance of molecular spacing and connection geometry. The 2-position attachment of the imidazo[1,2-a]pyridine-carboxamide group supported potent CK1α degradation, whereas changing the carbonyl attachment to the 3-position reduced degradation potency by more than tenfold. Additional methylene groups also disrupted degradation in selected analogs. These findings demonstrate that molecular flexibility and interfragment distance must be optimized together rather than assuming that a longer connection improves target accessibility.

The amide group is another useful structural feature because it can introduce conformational restriction and additional hydrogen-bonding potential. In the QXG series, selected amide-containing derivatives showed improved degradation profiles, while the position and orientation of the heteroaromatic group remained important. A focused series varying amide orientation, attachment position, and heterocyclic substitution can therefore provide useful information about the geometry required for CK1α recognition.

Conventional bifunctional linker design becomes necessary when the target-binding element and E3 ligase recruiter are separate molecular fragments. For example, an ATP-competitive CK1α inhibitor connected to a CRBN- or VHL-binding ligand would require a conventional PROTAC linker. In this case, solvent-exposed attachment positions, PEG or alkyl spacer length, heterocyclic rigidification, and linker polarity should be evaluated systematically. However, these variables belong to an exploratory bifunctional degrader architecture and should not be confused with the linker-free mechanism of established CK1α molecular glues.

• Attachment position: Prioritize the solvent-exposed C5 region of lenalidomide-derived scaffolds when introducing target-facing substituents. Compare alternative positions only when the CRBN-binding geometry can be preserved.
• Interfragment distance: Avoid unnecessary methylene extension. The QXG series demonstrates that even one additional methylene group can disrupt productive molecular glue activity.
• Connection chemistry: Compare direct carbon-carbon attachment and amide-based connections, considering their effects on conformation, hydrogen bonding, and molecular stability.
• Heterocycle orientation: Preserve favorable nitrogen positioning and attachment geometry around the Lys18 recognition region. The 2-position connection of the imidazo[1,2-a]pyridine group provides a useful reference.
• Bifunctional linker exploration: If developing an ATP-site CK1α PROTAC, establish a separate attachment-site and linker-length matrix rather than directly applying molecular glue SAR assumptions.

E3 Ligase Selection: CRBN Engagement and the Limits of a Single-Ligase Strategy

CRBN is the established E3 ligase recruiter for the reported CK1α molecular glue degraders. As the substrate-recognition component of the CUL4-DDB1-CRBN complex, CRBN binds the glutarimide-containing region of the molecular glue through its tri-tryptophan pocket. The recruited CK1α protein is then positioned near the ubiquitination machinery, allowing target ubiquitination and subsequent proteasomal degradation.

The structural interaction between the glutarimide ring and CRBN is essential, but it is not sufficient to predict CK1α degradation potency. The solvent-exposed portion of the molecule also influences the target-facing interaction surface. SJ3149 provides a clear example: its optimized benzisoxazole substituent contributes additional interactions involving CRBN His353 and Glu377 while also stabilizing CK1α recognition through Lys18 and the N-terminal degron. This illustrates why E3 ligand selection should be evaluated together with the complete molecular glue structure.

The CRBN dependence of a new CK1α molecular glue should be established through complementary experiments. CRBN knockout or knockdown models can determine whether degradation requires the intended E3 ligase. Competition with a CRBN-binding ligand and rescue through proteasome inhibition provide additional evidence for the proposed degradation mechanism. Target ubiquitination and ternary-complex formation measurements can further distinguish productive recruitment from simple molecular binding.

However, CRBN should not be assumed to be the only possible E3 ligase for future CK1α degrader development. VHL and other E3 ligases may provide alternative recruitment systems for bifunctional CK1α PROTACs, particularly when the selected target-binding warhead recognizes the ATP pocket or another protein-interaction surface. Their suitability must be established experimentally because the established N-terminal molecular glue recognition mechanism is specifically associated with CRBN.

Another consideration is the neosubstrate profile of the recruited E3 system. Modifying a CRBN-binding scaffold can change the recruitment of proteins such as IKZF1, IKZF2, IKZF3, and GSPT1. A compound that achieves potent CK1α degradation may therefore still be unsuitable if it produces unwanted protein depletion. Global proteomics, target-specific immunoblotting, and matched CRBN-dependence experiments should be incorporated into the selection process.

Table 3. Structure-Guided Design Considerations for CRBN-Directed CK1α Molecular Glue Degraders.

ATP-Competitive PROTACs Built on CK1α Kinase Inhibitor Warheads

Target Site: The ATP Pocket, Gatekeeper Region, and Solvent-Exposed Exit Vectors

The CK1α kinase domain contains a conventional ATP-binding pocket positioned between its N-terminal and C-terminal lobes. The pocket includes the nucleotide-binding region, hinge interactions, and catalytic elements required for phosphorylation. Structural information from CK1α kinase-domain complexes provides a basis for evaluating inhibitor binding modes and identifying potential positions for linker attachment.

The ATP pocket should not be considered a completely isolated cavity. The surrounding gatekeeper region, back-pocket accessibility, DFG motif, activation loop, and adjacent substrate-binding surface can influence ligand orientation and conformational preference. Mutations such as E98K and D140A are particularly relevant because they occur within the catalytic cleft and can alter its local chemical environment. These structural differences may affect the positioning of an inhibitor-derived warhead and its ability to retain binding after linker installation.

A suitable PROTAC warhead should preserve the key interactions that stabilize its parent inhibitor within the ATP pocket while presenting a substituent toward the surrounding solvent. The most useful attachment position is therefore not necessarily the position that provides the highest inhibitor potency. Instead, it should offer a practical exit vector that allows the attached linker and E3 recruiter to extend without blocking the essential hinge-binding interactions.

Warhead Selection: CK1 Family Inhibitor Scaffolds and Isoform Selectivity Risks

ATP-competitive CK1α inhibitors provide potential starting materials for inhibitor-derived PROTAC exploration. BAY-204 is an example of a potent ATP-competitive CK1α inhibitor that has been used to investigate the consequences of kinase inhibition. More recently, a 7H-pyrrolo[2,3-d]pyrimidine inhibitor series was reported, with compound 7a showing an IC₅₀ of approximately 10.96 nM in the reported CK1α assay. These compounds provide useful starting points for evaluating kinase-pocket recognition, although their inhibitor activity does not establish that they can function as effective degrader warheads.

Other CK1-family inhibitor scaffolds, including IC261 and D4476, may also provide reference structures for investigating kinase-domain recognition. However, their reported activities vary across CK1 isoforms and experimental assay conditions. A compound that inhibits CK1δ or CK1ε should not automatically be regarded as a selective CK1α ligand. Differences in ATP concentration, protein construct, kinase preparation, and assay format can also influence apparent potency.

For CK1α PROTAC development, warhead selection should therefore combine biochemical inhibition data with direct binding evidence and structural assessment. The parent inhibitor, linker-bearing intermediate, and complete degrader should be evaluated separately. If linker installation substantially weakens CK1α engagement, the attachment position or warhead scaffold should be reconsidered before expanding the E3 recruiter series.

• Potency and binding mode: prioritize CK1α inhibitor scaffolds with reproducible biochemical activity and a sufficiently characterized ATP-pocket binding mode.
• Isoform selectivity: compare CK1α against CK1δ, CK1ε, and other relevant kinase-family members to identify cross-reactivity before conjugation.
• Attachment-site tolerance: identify peripheral substituents that can be modified without removing essential hinge hydrogen bonds or hydrophobic pocket contacts.
• Warhead derivatization: compare the parent inhibitor, linker-bearing intermediate, and completed PROTAC to determine whether the target-binding mode is retained.

Linker Design: Attachment Point, Length, and Polarity from the ATP Pocket

Linker design for an ATP-site CK1α PROTAC should begin with the solvent-exposed portion of the bound inhibitor. The linker should extend away from the hinge-binding region and avoid occupying the narrow space between the kinase lobes. If the attachment position is too close to an essential hydrogen-bonding group, even a relatively short linker may disrupt the original target-binding mode.

A focused linker matrix can compare PEG-based, alkyl, and heterocycle-containing structures. PEG segments can improve aqueous compatibility, while alkyl chains may provide additional conformational freedom and hydrophobic interactions. Piperidine, piperazine, and other heterocyclic units can introduce conformational restrictions that may help control the relative orientation of CK1α and the recruited E3 ligase. These structures should be compared rather than assuming that one linker class is universally preferred.

Length optimization should be conducted using matched series in which the warhead and E3 ligand remain unchanged. Short linkers may prevent the ligase from approaching the target surface, whereas excessively long linkers can increase molecular size, flexibility, and conformational uncertainty. Linker polarity must also be considered because the kinase-binding warhead may already contain hydrophobic aromatic groups. An overly lipophilic linker can reduce aqueous solubility, while excessive polarity can limit intracellular exposure.

Since no experimentally established CK1α ATP-pocket PROTAC series was identified in the literature reviewed here, the optimal linker length and attachment position remain open design questions. Molecular docking, ternary-complex modeling, and a small matched synthesis matrix should be used to establish a productive starting architecture.

E3 Ligase Selection: CRBN vs. VHL Recruitment for ATP-Site CK1α PROTACs

CRBN and VHL are useful comparison systems for exploratory ATP-site CK1α PROTAC development. CRBN has a strong target-specific precedent because it supports natural CK1α molecular glue degradation. However, this does not automatically establish that a CRBN-recruiting ligand will produce a productive ternary complex when attached to an ATP-pocket inhibitor through a conventional linker.

VHL provides an orthogonal E3 recruitment system that can help determine whether the target-bound kinase surface is compatible with a different ligase orientation. A matched comparison between CRBN- and VHL-recruiting compounds can reveal whether weak degradation originates from an unsuitable target-binding vector, unfavorable linker geometry, or poor E3 recruitment.

The complete degrader should be evaluated for E3 expression, target engagement, ternary-complex formation, ubiquitination, and protein depletion. A strong binary interaction with CK1α or an E3 ligand is not sufficient evidence of productive degradation. If an ATP-site PROTAC retains inhibitor activity but does not reduce CK1α protein abundance, it should be treated as a kinase inhibitor conjugate rather than a validated degrader.

Table 4. Exploratory ATP-Site CK1α PROTAC Design Matrix.

Degraders Directed at the CK1α Substrate-Binding Cleft and Protein-Protein Interfaces

Target Site: Substrate-Binding Cleft, MDMX-Binding Surface, and FAM83/SACK1 Docking Sites

CK1α contains several protein-interaction surfaces beyond its ATP-binding pocket. One important region is the substrate-binding cleft between the N-terminal and C-terminal kinase lobes. This region participates in substrate recognition and contains recurrent CK1α mutation sites, including E98 and D140. These mutations have been associated with altered interactions between CK1α and MDMX, demonstrating that the local structure of the catalytic cleft can influence protein-complex formation in addition to kinase activity.

MDMX, also known as MDM4, is an important CK1α-interacting protein. The MDMX acidic domain and zinc-finger region contribute to its association with CK1α. CK1α can phosphorylate MDMX and regulate the interaction between MDMX and p53. Studies of E98K and D140A CK1α variants have shown increased MDMX association and altered MDMX-p53 interaction. These observations provide a biological basis for investigating the CK1α-MDMX interaction surface as a potential degrader-recognition site.

Another important group of CK1α interaction partners comprises the FAM83 protein family, also described as SACK1A-H. These proteins interact with CK1α through their conserved SACK1 domain, influencing its intracellular localization and access to different substrate populations. For example, SACK1D helps recruit CK1α to the mitotic spindle, whereas other SACK1 family members participate in different intracellular signaling complexes. These interactions are relevant because CK1α degradation can affect not only the target itself but also the stability of associated proteins.

The structural distinction between these interfaces is important. The MDMX-associated surface is linked to the substrate-binding cleft, whereas the SACK1 interaction is mediated by a protein-scaffold recognition mechanism. Neither should be treated as an established deep small-molecule pocket. Their potential use in degrader development therefore depends on identifying sufficiently stable recognition elements through structural mapping and experimental binding analysis.

Warhead Selection: Cleft-Directed Ligands and Peptidomimetic Interface Binders

Small molecules that interact with the CK1α substrate-binding cleft could provide an alternative to ATP-competitive inhibitors. The first design direction is to identify compounds that recognize peripheral residues around the cleft rather than relying exclusively on ATP competition. This approach may provide additional opportunities for selectivity if the selected recognition surface differs sufficiently from those of related CK1 family members.

A second direction is the development of peptidomimetic binders based on CK1α-interacting protein sequences. The MDMX acidic domain and zinc-finger-associated interaction region provide possible starting points for identifying peptide segments that recognize CK1α. Similarly, the conserved SACK1 domain of FAM83 proteins can be investigated to identify minimal binding elements capable of maintaining CK1α recognition.

These strategies remain exploratory. Functional evidence for a protein interaction does not automatically establish that the interface can be targeted by a stable peptide or small molecule. The selected warhead should demonstrate direct CK1α binding, sufficient affinity, and a defined attachment position before it is incorporated into a bifunctional degrader. Particular attention should be given to distinguishing a ligand that merely disrupts CK1α binding to a partner from one that can support productive E3 ligase recruitment and target degradation.

Linker Design: Reaching the E3 Ligase from a Shallow, Charged Interface

Protein-interaction-directed degraders present a different linker-design challenge from ATP-pocket PROTACs. The substrate-binding and partner-recognition surfaces are relatively broad and may contain charged or solvent-exposed residues rather than a deep hydrophobic cavity. The selected linker attachment site must therefore preserve the recognition surface while allowing the E3 recruiter to approach the target from an accessible direction.

For small-molecule interface binders, solvent-exposed substituents should be prioritized as potential linker attachment points. For peptide or peptidomimetic binders, terminal attachment positions may provide a practical starting point, provided that the interaction-critical residues remain accessible. Short flexible spacers can initially be compared with partially rigidified alternatives to determine whether the recruited ligase can approach the CK1α surface without steric interference.

The native CK1α interaction network should also be considered. If the selected warhead binds a surface already occupied by MDMX or a SACK1 protein, the apparent binding affinity and degradation profile may vary depending on the cellular complex state. It may therefore be necessary to evaluate both isolated CK1α and relevant CK1α-containing protein complexes during the early design process.

E3 Ligase Selection: Matching Ligase Recruitment to the CK1α Complex Landscape

CRBN provides the most relevant reference system because it is already known to recognize the CK1α N-terminal degron in the presence of molecular glue compounds. However, an interface-directed warhead may bind a different region of CK1α, and the resulting target orientation may not be compatible with the same CRBN recruitment geometry. CRBN should therefore be evaluated as a starting point rather than assumed to be universally suitable for every CK1α-binding surface.

VHL can provide a complementary E3 ligase system for determining whether an alternative recruiter improves ternary-complex formation. The comparison should focus on the orientation of the recruited ligase relative to the CK1α surface, rather than simply comparing the binary affinity of the E3 ligands. If the target is associated with MDMX or SACK1 proteins, the potential effects of native complex occupancy on ligase access should also be considered.

An important research consideration is partner co-degradation. Recent studies have shown that CK1α molecular glue compounds can promote degradation of associated SACK1 proteins in a CK1α-dependent manner. This means that a decrease in a partner protein does not necessarily indicate direct recruitment of that protein by the molecular glue. Protein-interaction disruption, CK1α-dependent co-degradation, and independent neosubstrate recruitment should be distinguished through appropriate genetic and biochemical controls.

Table 5. Exploratory CK1α Substrate-Cleft and Protein-Interaction-Directed Degrader Design Matrix.

Degrader Design for CK1α Mutation Hotspots

Target Site: Structural Consequences of the E98, D136, and D140 Mutations

CK1α mutations can influence kinase activity, substrate recognition, and protein-interaction behavior. Among the functionally characterized variants, E98 and D140 are particularly relevant because recurrent substitutions at these positions have been identified in the catalytic cleft. E98K and D140A have been investigated for their effects on CK1α interaction with MDMX and downstream p53 regulation. These substitutions can change local charge, hydrogen-bonding potential, and the geometry of the substrate-recognition surface.

E98 is positioned near the catalytic cleft, and replacement of glutamate with lysine reverses the local charge. This change can modify electrostatic interactions and the organization of neighboring residues. Other reported substitutions at this position, including E98G, E98N, and E98V, may produce different structural effects because they differ in side-chain size, polarity, and hydrogen-bonding potential. These variants should not be treated as structurally equivalent.

D140 is another important position associated with the substrate-binding region. D140A removes the acidic side chain and changes the local interaction environment. Other substitutions, including D140H and D140Y, introduce different chemical and steric properties. D136 is particularly important because it is a catalytic residue involved in kinase activity. D136N is useful as a kinase-inactive research control, but it should not be automatically classified as a recurrent disease-associated mutation hotspot.

For degrader design, these mutations should be evaluated according to their structural location and biological consequences. E98 and D140 substitutions may influence the substrate-binding cleft and protein-interaction surfaces, whereas D136 substitutions can directly affect catalytic function. None of these observations alone establishes that a particular variant will be resistant or sensitive to molecular glue-induced degradation.

Warhead Selection: Mutation-Agnostic vs. Mutation-Selective CK1α Binders

A mutation-agnostic degrader is generally the more practical starting point when the intended target population includes wild-type CK1α and several mutation variants. The established CRBN molecular glue mechanism recognizes the N-terminal β-hairpin degron rather than the E98 or D140 catalytic-cleft region. Consequently, mutations located in the kinase domain may not directly disrupt the molecular glue recognition surface.

Nevertheless, a mutation can alter protein conformation, stability, localization, or the formation of native protein complexes. A mutation-agnostic molecular glue should therefore be evaluated against a matched panel containing wild-type CK1α, E98K, D140A, and other relevant variants. The N-terminal degron should be confirmed to remain intact in each construct.

Mutation-selective binders may become useful when a substitution produces a distinctive chemical environment or creates a favorable interaction that is absent in the wild-type protein. For example, an inhibitor-derived warhead may be redesigned to recognize a mutation-associated pocket geometry or local electrostatic environment. However, no established mutation-selective CK1α degrader series has been demonstrated for E98 or D140 variants. Such designs should be treated as exploratory and supported by direct structural and binding evidence.

Linker Design: Preserving Degradation Across Wild-Type and Mutant CK1α

Linker design should be evaluated separately from mutation-dependent warhead recognition. If a molecular glue binds the conserved N-terminal degron, a conventional linker is not required. In this case, the primary objective is to preserve the molecular geometry responsible for CRBN recruitment and CK1α recognition across the different protein variants.

For bifunctional ATP-site or interface-directed degraders, mutation-specific structural differences may change the orientation of the bound warhead. A linker that works well with wild-type CK1α may therefore produce a less productive ternary complex with a mutant protein. The most informative approach is to use matched warhead-linker-E3 combinations across the same mutation panel.

Linker length, rigidity, and polarity should be varied systematically while keeping the target-binding scaffold and E3 recruiter constant. If a mutant retains warhead binding but shows reduced degradation, a different linker trajectory or E3 recruitment geometry may improve the outcome. However, if the mutation directly disrupts the target-binding interaction, linker extension alone is unlikely to solve the problem.

E3 Ligase Selection: CRBN Dependence and Alternative Ligases for Mutant CK1α

CRBN is the most evidence-supported E3 ligase for CK1α degradation, and it should be included as the primary reference system when evaluating mutant CK1α. Because the molecular glue recognition surface is located in the N-terminal degron, the effects of E98 and D140 mutations should be assessed experimentally rather than assumed to eliminate CRBN recruitment.

A useful experimental design compares CRBN-dependent degradation of wild-type and mutant CK1α under matched conditions. Measurements should include ternary-complex formation, target ubiquitination, degradation depth, and time-dependent recovery. A CRBN knockout or competition experiment can help confirm that observed protein reduction is mediated by the intended E3 ligase.

VHL can be included as an alternative E3 recruiter in bifunctional degrader programs, particularly when an ATP-site or interface-directed warhead is used. However, its performance against CK1α mutants has not been established as a general rule. The preferred E3 ligase should be determined from the complete ternary-complex architecture and the specific mutation profile rather than selected solely according to the affinity of its isolated ligand.

Table 6. CK1α Mutation-Aware Degrader Design Matrix.

Dual- and Multi-Target CK1α Degraders

Target Site: Pairing CK1α Engagement with IKZF2 or CDK7/9 Recruitment

Dual-target CK1α degradation has already been demonstrated through CRBN-dependent molecular glue compounds that recruit both CK1α and IKZF2. DEG-35 and DEG-77 are representative examples. Their development shows that a single molecular glue scaffold can support the recruitment of more than one target protein when the relevant neosubstrate surfaces are compatible with the same CRBN-binding architecture.

The CK1α-IKZF2 strategy is particularly interesting because the two proteins have different structural architectures. CK1α is a serine/threonine kinase with an N-terminal degron, whereas IKZF2 is a zinc-finger transcription factor with a distinct CRBN-recognition surface. A dual-target molecular glue must therefore accommodate two different protein-recognition mechanisms while maintaining suitable CRBN engagement.

CDK7 and CDK9 are also relevant in multi-target CK1α research because compounds such as BTX-A51 have demonstrated combined kinase-inhibitory activity against CK1α, CDK7, and CDK9. However, this is a multi-kinase inhibition strategy, not evidence of a CK1α/CDK7/CDK9 molecular glue degrader. No experimentally validated CK1α/CDK7 or CK1α/CDK9 dual degrader was identified in the literature reviewed here. These combinations should therefore be treated as exploratory design concepts rather than established degradation mechanisms.

Warhead Selection: Single-Scaffold Dual Degraders vs. Chimeric Designs

A single-scaffold molecular glue offers an attractive starting point for dual-target CK1α degradation. DEG-35 demonstrates that a CRBN-binding scaffold can support the degradation of CK1α and IKZF2 without requiring two independently attached target-binding warheads. Its initial structure contained a naphthamide-related recognition element, and the dual-target profile was identified through proteomic analysis.

DEG-77 provides an example of scaffold replacement to improve the overall molecular properties of a dual degrader. Replacing the naphthalene-containing portion of DEG-35 with a 2H-chromene-related structure improved solubility while retaining activity against both intended targets. The study also showed improved selectivity against other CRBN neosubstrates, including GSPT1, IKZF1, and IKZF3.

For future designs, the preferred approach is to begin with a molecular glue scaffold that already shows activity against CK1α and then determine whether an additional target can be recruited without compromising the original degradation profile. A chimeric design containing two independent target-binding elements may be considered when a single-scaffold approach is insufficient, but it introduces additional molecular size, flexibility, and selectivity challenges.

The most important selection criterion is the intended target combination. If the objective is CK1α and IKZF2 degradation, DEG-35 and DEG-77 provide direct precedents. If CDK7 or CDK9 is included, the project should first establish whether the intended mechanism is dual kinase inhibition, dual protein degradation, or a combination of these mechanisms.

Linker Design: Balancing Two Degradation Profiles in One Molecule

Dual-target molecular glues generally do not use the conventional long linker architecture of a bifunctional PROTAC. Instead, the scaffold itself provides the structural features needed to stabilize the interaction between CRBN and multiple target proteins. This makes the arrangement of aromatic rings, heterocycles, amide groups, and glutarimide-containing regions particularly important.

The rigid amide connection in DEG-35 provides a useful example of how local molecular geometry can influence the CK1α interaction. The structure-activity relationship work indicated that the amide contributes to CK1α recognition and helps maintain the molecular arrangement required for productive degradation. DEG-77 subsequently demonstrated that scaffold replacement can improve solubility without eliminating the dual-target activity.

For new multi-target molecular glue designs, modifications should be evaluated against each intended target separately. A compound may show strong CK1α degradation but weaker IKZF2 degradation, or vice versa. Time-dependent degradation and concentration-response profiles are therefore essential. Proteomic studies should also be used to identify additional neosubstrates that may be recruited at higher concentrations or longer exposure times.

If a future CK1α/CDK7 or CK1α/CDK9 bifunctional PROTAC is developed, conventional linker variables will become more important. The linker must preserve CK1α binding while allowing the second target-binding element and E3 recruiter to form productive complexes. Such designs should be optimized through matched attachment-site, length, and rigidity series rather than simply combining two potent kinase inhibitors.

E3 Ligase Selection: CRBN-Centric Design and Neosubstrate Off-Target Control

CRBN is the established E3 ligase for the reported CK1α/IKZF2 dual degraders. DEG-35 and DEG-77 both use CRBN-dependent recruitment, demonstrating that a single E3 ligase can support the degradation of multiple target proteins within one molecular glue architecture.

However, expanding the number of intended targets can increase the complexity of neosubstrate selectivity. DEG-35 showed moderate GSPT1 degradation at higher concentrations, whereas DEG-77 provided a more selective profile. Other CRBN substrates, including IKZF1 and IKZF3, should also be monitored when developing CK1α/IKZF2 dual degraders. The desired target combination should be distinguished from unintended degradation of additional proteins.

Proteomic analysis is particularly important because a molecular glue may recruit different proteins depending on their expression, accessibility, and interaction environment. A useful development workflow combines CRBN-binding measurements, target-specific degradation assays, global proteomics, and competition experiments. For proposed CK1α/CDK7 or CK1α/CDK9 degrader designs, CRBN should be considered a candidate recruiter rather than an established choice until direct target recruitment and degradation are demonstrated.

Table 7. Representative and Exploratory Dual-Target CK1α Degrader Strategies.

BOC Sciences Support for CK1α Degrader Development

CK1α Target Assessment and Degrader-Type Feasibility Evaluation

• Evaluate CK1α sequence, kinase-domain structure, N-terminal degron accessibility, and relevant splice variants.
• Compare molecular glue, ATP-site PROTAC, and protein-interaction-directed degrader strategies according to the intended target form.
• Assess E98, D136, and D140 variants and identify potential effects on target recognition and protein-interaction behavior.

CK1α Warhead, Molecular Glue, and Linker Design Support

• Evaluate lenalidomide-derived CRBN-binding scaffolds, target-facing heterocycles, and potential CK1α recognition elements.
• Identify ATP-pocket inhibitor attachment positions and explore alternative substrate-cleft or protein-interaction-directed binders.
• Optimize linker length, composition, polarity, and rigidity for bifunctional degrader architectures.

Custom Degrader Synthesis and E3 Ligase System Development

• Prepare customized CK1α molecular glue analogs, inhibitor-derived PROTACs, and peptide-based degrader candidates.
• Provide CRBN and VHL recruiter selection, linker conjugation, and matched degrader library construction.
• Support peptide and peptidomimetic architectures for investigating CK1α-MDMX and CK1α-SACK1 interactions.

Degradation, Selectivity, and Mechanism Evaluation

• Measure CK1α degradation potency, maximum degradation, and time-dependent protein recovery.
• Confirm E3 ligase dependence, target ubiquitination, and proteasome-mediated degradation.
• Evaluate selectivity against related CK1 family members, CRBN neosubstrates, and proteins associated with native CK1α complexes.

Explore featured products that can expand your research options and accelerate your next discovery.

Access end-to-end service solutions that help bring efficiency, flexibility, and expertise to your research pipeline.

News

• Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology
• Degrader Building Blocks for Targeted Protein Degradation
• Recent Progress of PROTACs Targeting Non-enzymatic Functional Proteins
• Discovery of Molecular Glue Degraders

Technical Information

• Proteolysis-Targeting Chimeras (PROTAC)
• Targeted Protein Degradation: The Next Frontier in Drug Discovery
• Overview of 12 Targeted Protein Degradation Technologies
• Peptide and Small Molecule Based PROTACs Technology